Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Conditions

• Cholangiocarcinoma Non-resectable
• Cholangiocarcinoma, Extrahepatic
• Cholangiocarcinoma, Intrahepatic
• Gallbladder Adenocarcinoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• PEGPH20 — DRUG
  PEGPH20 will be administered as per the schedule specified in the respective arms.
• CIS — DRUG
  CIS will be administered as per the schedule specified in the respective arms.
• GEM — DRUG
  GEM will be administered as per the schedule specified in the respective arms.
• Atezolizumab — DRUG
  Atezolizumab will be administered as per the schedule specified in the respective arms.

Study Details

The study is being conducted to assess the safety and tolerability of (1) PEGPH20 in combination with CIS and GEM (PEGCISGEM), and (2) PEGPH20 in combination with CIS, GEM, and atezolizumab (PEGCISGEMATEZO) compared with (3) cisplatin and gemcitabine (CISGEM).

Key Dates

Start date

Oct 2, 2017

Status verified

Jan 2020

Primary completion

Nov 11, 2019

Completion

Nov 11, 2019

Study Design

Enrollment

85 participants (actual)

Allocation

RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: Run-in Portion: PEGCISGEM
  Participants will receive 3.0 micrograms per kilogram (mcg/kg) PEGPH20 on Days 1, 8, and 15 in combination with 25 milligrams per meter square (mg/m\^2) of CIS plus 1000 mg/m\^2 of GEM administered on Days 2 and 9 of each 21-day cycle by intravenous (IV) infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
• Experimental: Run-in Portion: PEGCISGEMATEZO
  After 6 participants from the PEGCISGEM arm are treated for at least 1 cycle without significant toxicities, new participants will be enrolled in this arm to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m\^2 of CIS and 1000 mg/m\^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
• Experimental: Expansion Portion: PEGCISGEM
  After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 25 mg/m\^2 CIS and 1000 mg/m\^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
• Experimental: Expansion Portion: PEGCISGEMATEZO Twice Weekly
  After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m\^2 of CIS and 1000 mg/m\^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
• Experimental: Expansion Portion: PEGCISGEMATEZO Once Weekly/Twice Weekly
  After the implementation of Protocol Amendment #3 and as communicated to the Investigators via a letter dated 22 March 2019, participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 4, 8, 11, 15 and 18 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 Cycle 1) plus 25 mg/m\^2 of CIS and 1000 mg/m\^2 GEM on Days 2 and 9 of Cycle 1 (cycle length = 21 days) by IV infusion. Participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m\^2 of CIS and 1000 mg/m\^2 GEM on Days 2 and 9 of each 21-day cycle from Cycle 2 and beyond by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
• Active Comparator: Expansion Portion: CISGEM
  After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the run-in portion safe and tolerable, new participants will be enrolled to receive 25 mg/m\^2 CIS and 1000 mg/m\^2 GEM on Days 1 and 8 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.

Primary Outcome Measure

Run-in Portion: Number of Participants With Adverse Events (AEs) [ Time Frame: From first exposure to study drug through 30 days after the end of treatment visit (maximum exposure: 508 days) ]

Locations (26)

Find similar trials in Phoenix, AZ

Related Studies

• Evaluating Novel Therapies in ctDNA Positive GI Cancers
  PHASE3 · Recruiting · Georgetown University · Washington D.C., District of Columbia
• Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
  PHASE2 · Recruiting · Beth Israel Deaconess Medical Center · Boston, Massachusetts
• CT-95 in Advanced Cancers Associated With Mesothelin Expression
  PHASE1 · Recruiting · Context Therapeutics Inc. · Denver, Colorado
• Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
  PHASE2 · Recruiting · Yale University · New Haven, Connecticut